logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
Showing 1 - 20 of 24 Items
Showing 1 - 20 of 24 Items
Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.
  • Current Page (20)
  • CSV
  • BibTeX
  • EndNote
  • All Results (24)
  • CSV
  • BibTeX
  • EndNote
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

The effectiveness and safety of bedaquiline, pretomanid, and linezolid (BPaL)-based regimens for rifampicin-resistant tuberculosis in non-trial settings - A prospective cohort study in Belarus and Uzbekistan

Sinha A, Klebe R, Rekart ML, Alvarez JL, Skrahina A,  et al.
2025-02-18 • Clinical Infectious Diseases
2025-02-18 • Clinical Infectious Diseases

BACKGROUND

Only 63% of patients initiating multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment in 2020 were treated successfully. 24-Wee...

Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Conference Material
|
Slide Presentation
Conference Material
|
Abstract
Journal Article
|
Research
Conference Material
|
Slide Presentation
Journal Article
|
Letter
Conference Material
|
Poster
Journal Article
|
Research
Journal Article
|
Research
Conference Material
|
Poster
Journal Article
|
Research
Conference Material
|
Abstract
Journal Article
|
Research
Conference Material
|
Poster

Supporting multidrug-resistant or rifampicin-resistant TB treatment adherence in people with harmful use of alcohol through person-centred care

Harrison RE, Shyleika V, Vishneuski R, Leonovich O, Vetushko D,  et al.
2024-11-06 • Oxford Medical Journal
2024-11-06 • Oxford Medical Journal

BACKGROUND

TB is concentrated in populations with complex health and social issues, including alcohol use disorders (AUD). We describe treatment adherence and o...

Second-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan

Moe S, Azamat I, Allamuratova S, Oluya M, Khristusev A,  et al.
2024-09-01 • IJTLD OPEN
2024-09-01 • IJTLD OPEN

BACKGROUND

Dru...

Yield of TB screening in prisons in Tajikistan

Moe S, Asozoda M, Aung A, Dusmatova Z, Akintore F,  et al.
2024-08-01 • IJTLD OPEN
2024-08-01 • IJTLD OPEN

BACKGROUND

The rate of TB in prison institutions is estimated to be 23 times higher than in the general population. Limited documentation exists regarding TB screening in Tajiki...

A 10-year review of isoniazid-resistant TB management in Uzbekistan 2009-2020

Rekart M, Thit P, Oluya M, Moe S, Hasan T,  et al.
2024-07-01 • IJTLD OPEN
2024-07-01 • IJTLD OPEN

Background

Isoniazid (INH, H) resistance is the most common drug-resistant TB pattern, with treatment success rates lower than those in drug-susceptible TB. The...

Trends in the availability and prices of quality-assured tuberculosis drugs: a systematic analysis of Global Drug Facility Product Catalogs from 2001 to 2024

Kohler S, Achar J, Mulder C, Sitali N, Paul N
2024-06-25 • Globalization and Health
2024-06-25 • Globalization and Health
BACKGROUND
The Global Drug Facility (GDF) of the Stop TB Partnership was launched in 2001 with the goal of increasing access to quality-assured tuberculosis (TB) drugs and products. ...

Household drug-resistant TB contact tracing in Tajikistan

Rekart ML, Aung A, Cullip T, Mulanda WK, Mun L,  et al.
2023-10-01 • International Journal of Tuberculosis and Lung Disease
2023-10-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
Tajikistan has a high burden of rifampicin-resistant TB (RR-TB), with 2,700 new cases estimated for 2021 (28/100,000 population). TB is spread among household members thro...

Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus

Yatskevich N, Hurevich H, Solodovnikova V, Garsevanidze E, Lachenal N,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023

Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus

Yatskevich N, Hurevich H, Solodovnikova V, Garsevanidze E, Lachenal N,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
INTRODUCTION
The total duration of treatment for rifampicin-resistant tuberculosis (RR-TB) in Belarus prior to December 2022 was 18-20 months. The efficacy of treatment with such reg...

Primary bedaquiline resistance in Karakalpakstan, Uzbekistan

Moe S, Rekart ML, Hernandez D, Sholpan A, Ismailov A,  et al.
2023-05-01 • International Journal of Tuberculosis and Lung Disease
2023-05-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND:
Bedaquiline (BDQ) is widely used in the treatment of rifampicin-resistant TB (RR-TB). However, resistance to BDQ is now emerging. There are no standardised regimens for ...

Safe motherhood and childhood in Sierra Leone: key findings from mixed-methods health-seeking behaviour study

Lavilla KM, Teal J, Schausberger B, Sankoh M, Conteh AB,  et al.
2022-05-11 • MSF Scientific Days International 2022
2022-05-11 • MSF Scientific Days International 2022

Family directly observed therapy for children with drug-resistant TB

Rekart ML, Morshed T, Mulanda WK, Klieascikova J, Sitali N,  et al.
2022-08-01 • International Journal of Tuberculosis and Lung Disease
2022-08-01 • International Journal of Tuberculosis and Lung Disease

Detection of Mycobacterium tuberculosis complex in the stool of pediatric patients using the Xpert MTB/Rif Ultra assay

Mun L, Gomez D, Sitali N, Rajabzoda A, Azamova S,  et al.
2022-05-09 • MSF Scientific Days International 2022
2022-05-09 • MSF Scientific Days International 2022

A framework for assessing import costs of medical supplies and results for a tuberculosis program in Karakalpakstan, Uzbekistan

Kohler S, Sitali N, Paul N
2021-08-25 • Health Data Science
2021-08-25 • Health Data Science

BACKGROUND

Import of medical supplies is common, but limited knowledge about import costs and their structure introduces uncertainty to budget planning, cost ma...

The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer, shorter, and short drug regimens for Karakalpakstan, Uzbekistan

Kohler S, Sitali N, Achar J, Paul N
2022-08-03 • PLOS Global Public Health
2022-08-03 • PLOS Global Public Health

Tuberculosis (TB) programs depend on a continuous supply of large amounts of high-quality TB drugs. When TB programs procure TB drugs from international suppliers, such as the Global ...

Patient and carer engagement in research agenda setting

Abramenko K, Shchenina K, Stringer B, Koerner L, Tan C,  et al.
2021-05-18 • MSF Scientific Days International 2021: Research
2021-05-18 • MSF Scientific Days International 2021: Research

Costs and import costs of past, present, and future TB drug regimens: a case study for Karakalpakstan, Uzbekistan

Kohler S, Sitali N, Achar J, Paul N
2022-11-23 • Journal of Public Health
2022-11-23 • Journal of Public Health
BACKGROUND
Tuberculosis (TB) drugs and their import are costly. We assessed how shorter TB drug regimens, which were non-inferior or superior in recent TB trials, can affect the cost...

Safe motherhood and childhood in Sierra Leone: key findings from mixed-methods health-seeking behaviour study

Lavilla KM, Teal J, Schausberger B, Sankoh M, Conteh AB,  et al.
2022-05-11 • MSF Scientific Days International 2022
2022-05-11 • MSF Scientific Days International 2022
INTRODUCTION
MSF and the MoHS implemented a partnership model of free and accessible maternal and child healthcare at primary and hospital-level health facilities in Tonkolili Distri...

Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan

Nair P, Hasan T, Zaw KK, Allamuratova S, Ismailov A,  et al.
2022-07-01 • International Journal of Tuberculosis and Lung Disease
2022-07-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The WHO recommends the use of bedaquiline (BDQ) in longer, as well as shorter, multidrug-resistant TB (MDR-TB) treatment regimens. However, resistance to this new drug is ...

A common agenda: experiences of involving patients and carers in setting research agendas for tuberculosis care

Shchenina K, Stringer B, Koerner L, Tan C, Vishneuski R,  et al.
2021-05-18 • MSF Scientific Days International 2021: Research
2021-05-18 • MSF Scientific Days International 2021: Research